This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mahlmann A, Gehrisch S, Beyer-Westendorf J (2013) Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 36:533–535
Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561
Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558
Xarelto Prescribing Information (2013). http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed 17 Dec 2013
Protocol for: Patel MR, Mahaffey KW, Garg J, et al. (2013) Rivaroxaban versus warfarin in nonvalvular atrial abrillation. N Engl J Med 2011; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_protocol.pdf. Accessed 17 Dec 2013
Protocol for: The EINSTEIN–PE investigators (2013). Oral rivaroxaban for the treatment of symptomatic pulmonary. N Engl J Med 2012; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1113572/suppl_file/nejmoa1113572_protocol.pdf. Accessed 17 Dec 2013
Protocol for: The EINSTEIN investigators (2013). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_protocol.pdf. Accessed 17 Dec 2013
Centers for Disease Control and Prevention (2013). National Health and Nutrition Examination Survey. Intake of calories and selected nutrients for the United States Population, 1999–2000. http://www.cdc.gov/nchs/data/nhanes/databriefs/calories.pdf. Accessed 17 Dec 2013
Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ (2012) Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 255:1100–1104
Magnani JW, Hylek EM, Apovian CM (2013) Obesity begets atrial fibrillation: a contemporary summary. Circulation 128:401–405
Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47:218–226
University of California San Francisco (2013). Dietary guidelines after bariatric surgery. http://www.ucsfhealth.org/education/dietary_guidelines_after_gastric_bypass/. Accessed 17 Dec 2013
Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568
Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137:1382–1390
Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546
Conflict of interest
Drs. Bareket and Thomas report receiving consulting fees from Janssen Pharmaceuticals, the manufacturer of rivaroxaban.
About this article
Cite this article
Thomas, Z., Bareket, Y. & Bennett, W. Rivaroxaban use following bariatric surgery. J Thromb Thrombolysis 38, 90–91 (2014). https://doi.org/10.1007/s11239-014-1057-6
- Atrial Fibrillation
- Gastric Bypass
- Caloric Intake
- Venous Thromboembolism